HotMasterAn innovative Hot Start/Cold Stop technology for better ,,, PCR* results
ents). ... Materials and methods ...All PCR reactions were performed in triplicate on the Eppendorf Master...1x PCR buffer 2.5 mM Mg ++ 0.2 ...Note that we have determined empirically that the optimal temperature ...
ents).
Materials and methods
All PCR reactions were performed in triplicate on the Eppendorf Mastercycler
gradient using human genomic DNA or Phage Lambda DNA (New England BioLabs,
USA) as indicated. The reaction components are:
1x PCR buffer
2.5 mM Mg++
0.2 M of each primer
0.2 mM dNTP's
1.25 units respective Taq polymerase
MBGW to 50 l total reaction volume
(Templates are indicated in each experiment)
Note that we have determined empirically that the optimal temperature
for the elongation step using HotMaster is 65C.
Experiment 1: Specificity
A 131 bp target in the human TNF gene was amplified using Eppendorf HotMaster
Taq DNA polymerase, a conventional chemically modified Hot Start DNA polymerase,
an antibody- mediated Hot Start DNA polymerase and standard Taq DNA polymerase.
The following reaction conditions were used:
Primers and Template:
Primers 131 bp TNF system
Forward Primer: GGTTTCGAAGTGGTGGTCTTG
Reverse Primer: CCTGCCCCAATCCCTTTATT
Template: 50 ng human gDNA
HotMaster Taq and Standard Taq cycling conditions:
Initial Denaturation:
None
35 cycles:
94C for 1 second
55C for 1 second
72C for 5 seconds
Hold:
10C
Chemically blocked Taq cycling conditions:
Initial Denaturation:
95C for 10 minutes
35 cycles:
94C for 1 second
55C for 1 second
'"/>Source:
Page: All 1 2 3 4 5 6 7 Related biology technology :1.
Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
(Date:11/23/2009)...re/--PearlTherapeuticsInc.,abiopharmaceuticalcompa...ronicrespiratorydiseases,todayannouncedtheappointm...osenhas25yearsofexperienceinthepharmaceuticalandbi...encesandALZACorporation.Hisappointmentincreasesthe...bringsawealthofproductdevelopment,commercializatio...
(Date:11/20/2009)... , , , , , , , ...f scientists from Washington University in St. Lou...Laboratory and Iowa State University has finished ... Click here for more information. , , ... , , , , , , , , , ...
(Date:11/20/2009)... -- Veridiam (www.veridiam.com) won the prestigiou...t the 2009 Workplace Excellence Awards. The awards...Resources Management and recognize innovative and ...iam was one of nine winners, selected from more th...e recent awards ceremony. San Diego-based Veridiam...
(Date:11/20/2009)...wswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ...en public offering of 6,800,000 shares of its comm...re. The approximately $21 million of net proceeds...ommissions, will be used for preclinical studies a...rnal research and development programs, working ca...
Breaking Biology Technology:Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Novavax Prices Public Offering of Common Stock 2...equirements with NASDAQ; Stock Symbol ,OGXI, Impl...nds cash runway while focusing on clinical pipeli...tCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly...e "Company") announced that the Company has comple...NASDAQ has approved the commencement of trading,in...
...inhua-PRNewswire-FirstCall/ --,China-Biotics, Inc....,Company"), a leading Chinese firm specializing in...and distribution of probiotics products,today anno...are,Pharmaceutical Co., Ltd. ("Square Pharmaceutic...l,s probiotics-based medicines. The agreement runs...
...CG Data Management and Supports Best-Of-Breed, C...egular Hardware and Soft...orporation, a leading,provider of fully integrated...nd Epiphany Cardiography Products, introduce Cardi...ftware for cardiac rhythm data,management. By deli...
Other Biology Technology:Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution 2...unogen Synthetic peptide: QAARQAATSVPNPP, corresp...BRF2. Reactivity / Specificity Cross-reacts with...nd Information BRF2 is one of the multiple subuni...complex required for transcription of genes with p...
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Anti-alpha/beta-Tubulin Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Biology Products: